1349902-20-0Relevant academic research and scientific papers
RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS
-
Page/Page column 40, (2019/04/26)
The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of
Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis
Guibbal, Florian,Bénard, Sébastien,Patché, Jessica,Meneyrol, Vincent,Couprie, Jo?l,Yong-Sang, Jennyfer,Meilhac, Olivier,Jestin, Emmanuelle
supporting information, p. 787 - 792 (2018/01/17)
Darapladib is one of the most potent Lp-PLA2 (Lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 0.25 nM. We demonstrate that a crucial step of Darapladib synthesis was not correctly described in the litera
Selective inhibitors and tailored activity probes for lipoprotein- associated phospholipase A2
Nagano, Joseph M.G.,Hsu, Ku-Lung,Whitby, Landon R.,Niphakis, Micah J.,Speers, Anna E.,Brown, Steven J.,Spicer, Timothy,Fernandez-Vega, Virneliz,Ferguson, Jill,Hodder, Peter,Srinivasan, Prabhavathi,Gonzalez, Tara D.,Rosen, Hugh,Bahnson, Brian J.,Cravatt, Benjamin F.
, p. 839 - 843 (2013/02/25)
Lipoprotein-associated phospholipase A2 (Lp-PLA2 or PLA2G7) binds to low-density lipoprotein (LDL) particles, where it is thought to hydrolyze oxidatively truncated phospholipids. Lp-PLA2 has also been implicate
NOVEL PROCESSES
-
, (2011/12/04)
This invention relates to methods of making a compound of formula (I) and intermediates for same. The compounds of formula (I) being useful for treating cardiovascular and inflammatory diseases such as atherosclerosis.
